Pharmaceutical Chemical Sermorelin Peptides Powder 2mg/Vial Sermorelin Acetate 86168-78-7

Pharmaceutical Chemical Sermorelin Peptides Powder 2mg/vial Sermorelin acetate 86168-78-7SermorelinBasic info:Product NameSermorelinSynonymSomatoliberin,SermorelinCAS NO86168-78-7Molecular FormulaC149H246N44O42SMolecular weight3357.96Purity98.0%min.AppearanceWhite powderCertificationGMP, ISO 9001, USP, BPSuitable forElderly, Children, AdultGradePharmaceutical GradeUsagexanthine oxidase inhibitorStorageStore in cool and dry area and keep away from direct sunlight.PackingDiscreet packing ways as your requirement, 100% go through.
Product Name: Sermorelin
Synonyms: Sermorelin acetate, GRF 1-29
CAS: 86168-78-7
MF: C149H246N44O42S
MW: 3357.88
Usage xanthine oxidase inhibitor
Mass Balance: 95.0~105.0%
Purity (HPLC): 99.5%min.
Single Impurity (HPLC): 1.0%max
Amino Acid Composition: about10% of theoretical
Peptide Content (N%): 80.0%min.
Water Content (Karl Fischer): 8.0%max.
Acetate Content (HPIC): 12.0%max.
MS (ESI): Consistent
Specific Rotation (20/D): -80.0~-90.0 degree(c=0.5 1%HAc)
Appearance: White powderDescription:This contributes to sermorelin's function as a secretagogue in this case, the substance whose secretion is promoted is growth horm. For this reason, sermorelin is often also referred to as an ' stimulator' and is considered an excellent alternative to .One important thing to understand about Sermorelin is that it promotes healthy function of the pituitary (the gland responsible for our body's production of ) during the aging process. This is a far cry from aggressive administration of which can, in fact, negatively impact normal pituitary function.Application:Changes in Body Composition Stimulators
Changes in body composition due to decreasing levels ofare reflected by a decrease in lean body mass (muscle) and an increase in fat mass. Correctinglevels has been shown to reverse this state by improving muscle mass and reducing fat.2. Bone Mineral Density
Research indicates that deficiency in adults contributes to a reduction in bone density and therefore increased risk of osteoporosis. It has also been shown that replacement therapy for greater than 12 months results in improved bone mineral density and hence, lower risk of osteoporosis.3. Muscle Strength
Due to changes in body composition detailed above, muscle strength is understandably compromised. As therapy corrects body composition and improves muscle mass, muscle strength also improves. The best results are gained after 12 months oftherapy.4. Joint Health
By improving bone mineral density and increasing muscle mass and strength, therapy can help to prevent joint deterioration that is a feature of arthritis. Optimal levels are also essential for health of connective tissue such as the synovium found in joints.5. Exercise Performance
Exercise performance is reduced in individuals with deficiency. This appears to be partially due to reductions in bone density and muscle mass but also in part due to a reduction in oxygen uptake. therapy for 6 months has been shown to improve exercise performance by improving muscle mass and also oxygen uptake6. Heart Health
There is evidence of a greater risk of heart disease in individuals with deficiency and it has been hypothesized that this is due to a greater propensity to develop premature atherosclerosis (a build-up of plaque inside the arteries which increases risk of heart attack and stroke). deficiency also results in changes in heart size and function. These changes have been demonstrated to be reversed after 6 months therapy.7. metabolism
deficiency results in a reduced resting metabolism and replacement therapy reverses this decrease. therapy has also been shown to increase protein synthesis, increase fat oxidation, normalize carbohydrate metabolism and reduce LDL (bad) cholesterol. These favorable effects on metabolism may in part explain some of the other benefits of including improved hearth health and body composition.8. Skin Thickness
A reduction in skin thickness and all-important skin collagen is another result ofdeficiency. Both conditions are improved by therapy.Related products lists:Product NameCAS No.SpecificationAOD-9604CAS 221231-10-32mg/vialCJC-1295DAC2mg/vialCJC-1295CAS 863288-34-02mg/vialDeslorelinCAS 57773-65-620mg/vialDSIPCAS 62568-57-42mg/vialEpitalonCAS 307297-39-810mg/vialFollistatin 3441mg/vialGDF-81mg/vialGHRP-2CAS 158861-67-75mg/vial10mg/vialGHRP-6CAS 87616-84-05mg/vial10mg/vialGonadorelinCAS 34973-08-52mg/vialHexarelinCAS 140703-51-12mg/vial176-1912mg/vial5mg/vialIpamorelinCAS 170851-70-42mg/vial5mg/vialMelanotan ICAS 75921-69-610mg/vialMelanotan IICAS 121062-08-610mg/vialMGF2mg/vial5mg/vialOxytocinCAS 50-56-62mg/vialPEG-MGF2mg/vialPentadecapeptide BPC 1572mg/vialPT141CAS 189691-06-310mg/vialSelank5mg/vialSermorelinCAS 86168-78-72mg/vialTB500CAS 75591-33-42mg/vial5mg/vialTesamorelinCAS 218949-48-52mg/vialTriptorelin AcetateCAS 57773-63-42mg/vial